Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (10): 1799-1802.doi: 10.3969/j.issn.1673-8225.2011.10.019

Previous Articles     Next Articles

Allogeneic bone marrow mesenchymal stem cells transplantation in treatment of acute liver failure

He Jin-qiu, Yang Ling-ling, Lei Yan-chang, Yang Wen-long, Zhou Xi-jing   

  1. First Department of Hepatology, Nanchang Municipal Ninth Hospital, Hospital of Infectious Diseases Affiliated to Nanchange University, Nanchang  330002, Jiangxi Province, China
  • Received:2010-08-18 Revised:2010-12-28 Online:2011-03-05 Published:2011-03-05
  • Contact: Yang Ling-ling, Master, First Department of Hepatology, Nanchang Municipal Ninth Hospital, Hospital of Infectious Diseases Affiliated to Nanchange University, Nanchang 330002, Jiangxi Province, China eleanyang2008@163.com
  • About author:He Jin-qiu, Professor, Chief physician, First Department of Hepatology, Nanchang Municipal Ninth Hospital, Hospital of Infectious Diseases Affiliated to Nanchange University, Nanchang 330002, Jiangxi Province, China yangwenlongjx@yahoo.com.cn
  • Supported by:

    the China Hepatitis Prevention and Treatment Foundation and Artificial Liver and Blood Purification Technology Foundation, No. SLDALBP200713*; the Supportive Project of Department of Science and Technology of Jiangxi Province*

PDF

409

Abstract:

BACKGROUND: Effective therapies are deficient in treating acute liver failure (ALF). At present, there is no effective method. Bone mesenchymal stem cells (BMSCs) can differentiate into hepatocyte-like cells and participate in liver regeneration and repair, which provides a new manner for treatment of ALF.
OBJECTIVE: To evaluate the effect of BMSCs transplantation on the ALF in rats, to provide empirical study foundation for future clinical application.
METHODS: The BMSCs were cultured and purified by the whole marrow-cultured method. A total of 30 healthy Sprague-Dawley rats were randomly assigned to three groups. Normal control group: no treatment. ALF group and transplantation group: ALF models of rats were developed by intraperitoneal injection with CCL4. 24 hours following model induction, physiological saline and an equal volume of BMSCs were injected via the caudal vein. Finally, liver function was tested at 1, 2, 3, 7 days intervals and histopathologic examinations were performed.
RESULTS AND CONCLUSION: Following BMSCs transplantation, the survival rates of the rats were increased to 70%, compared to the ALF group (20%), and the difference was statistically significant (P < 0.05). The activities of alanine aminotransferase and aspartate aminotransferase were significantly lower in the transplantation group compared with ALF group (P < 0.05). In pathohistology, the degeneration and necrosis of hepatic cells and degree of inflammation were less obvious than that of ALF group. Hence, BMSCs transplantation via caudal vein could elevate the survival rate of ALF rats, improve hepatic function and alleviate the degree of cell necrosis, and could help to treat ALF in rats.

CLC Number: